Day One Biopharmaceuticals

Now a part of Servier Group. Focused on developing better, targeted medicines faster for patients of all ages who need new options.

[Day One Biopharmaceuticals @DayOneBio]

What are you most excited about at the meeting this year? Stop by and say hello at booth #36155 and #12079.

[Servier Pharmaceuticals @ServierPharma]

We’re bringing the #Servier mission to life at #ASCO26!

We asked a few members of our team to share what they’re most excited about at this year’s meeting.

Hear directly from employees as they reflect on the science, collaboration, and progress shaping the future of oncology.

[Day One Biopharmaceuticals @DayOneBio]

New data on our investigational medicine for adenoid cystic carcinoma (ACC) at #ASCO26! These new insights in the ACC population will be presented during an oral session today highlighting an encouraging profile with early anti-tumor activity. More details in today’s release here: https://t.co/1II2YQ4SN2

[Day One Biopharmaceuticals @DayOneBio]

#ASCO26 is underway, and we're excited to be part of the conversation shaping the future of oncology care. Stop by booths #36155 and #12079 to connect with our teams and learn about our ongoing work to advance cancer research and treatment.

[Servier Pharmaceuticals @ServierPharma]

We’re excited to be here at #ASCO26!

Come visit booth #12079 & #36155 to connect with our team and discover how we’re driving progress across a range of rare cancers, including IDH-mutated glioma and adenoid cystic carcinoma (ACC).

Learn more: https://t.co/kmLs0G0BGp

[Day One Biopharmaceuticals @DayOneBio]

We're excited to join the oncology research and care community at #ASCO26 next week!

Our team will be presenting new data for our investigational medicine for patients with the adenoid cystic carcinoma (ACC) during an oral presentation on June 1. Learn more here: https://t.co/rjV3mLomqt

Heading to #ASCO26? Visit us at booth #36155.

[Day One Biopharmaceuticals @DayOneBio]

Today we've announced the completed enrollment in the FIREFLY-2 clinical trial, evaluating our medicine as a front-line treatment for pediatric low-grade glioma (pLGG). This is another step forward in our work to evolve the pLGG treatment paradigm and ultimately establish a new standard of care for patients newly diagnosed with pLGG. Read more: https://t.co/UTpuY9fyNU

[Day One Biopharmaceuticals @DayOneBio]

Today, @ServierPharma announced the successful completion of the acquisition of Day One. Learn more: https://t.co/flpDgWR2uh

[Day One Biopharmaceuticals @DayOneBio]

Today we’ve announced a definitive agreement to be acquired by @Servier. Servier shares our deep commitment to advancing innovation in cancer along with our patient-focused methodology to address the most pressing areas of unmet need. Please refer to today’s press release for important information about this transaction. https://t.co/SG6yYPqFw0

[Day One Biopharmaceuticals @DayOneBio]

Day One reports fourth quarter and full year 2025 financial results. Read more: https://t.co/TjSq3bPNNZ

[Day One Biopharmaceuticals @DayOneBio]

Day One announces preliminary 2025 OJEMDA Net Product Revenue and provides 2026 Revenue Guidance ahead of CEO Jeremy Bender's presentation at #JPM26 today at 5:15 pm PT. Read the press release here: https://t.co/DfgjFrPcdJ

[Day One Biopharmaceuticals @DayOneBio]

Today we've completed the acquisition of Mersana Therapeutics, expanding our pipeline with a clinical-stage antibody drug conjugate (ADC) emiltatug ledadotin (Emi-Le) targeting adenoid cystic carcinoma (ACC).

This program is well aligned to our mission to develop innovative medicines for patients who urgently need them and broadens our opportunity for patient impact and continued growth.

Read the press release here: https://t.co/EJTH5zbsBq

[Day One Biopharmaceuticals @DayOneBio]

Day One announces our three-year results from the Phase 2 FIREFLY-1 trial, presented in an oral presentation at the Society for Neuro-Oncology (SNO) Annual Meeting #SNO2025. Learn more here: https://t.co/CtJkhJzMY9

[Day One Biopharmaceuticals @DayOneBio]

Join Dr. Cassie Kline on Sunday, November 23 at the Society of Neuro-Oncology (SNO) Annual Meeting to hear the three-year follow-up data from the Phase 2 FIREFLY-1 trial.

#SNO2025

[Day One Biopharmaceuticals @DayOneBio]

Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases. Read more: https://t.co/xJ78pYWmuh

[Day One Biopharmaceuticals @DayOneBio]

Day One reports third quarter 2025 financial results. Read more: https://t.co/98KVSG4rTD

[Day One Biopharmaceuticals @DayOneBio]

Day One reports second quarter 2025 financial results. Read more: https://t.co/q9Rt3YEvXx

[Day One Biopharmaceuticals @DayOneBio]

We’re thrilled to announce that Michael Vasconcelles, M.D., has joined Day One as Head of Research & Development (R&D). Mike brings more than 25 years of experience in oncology research and development as an academic hematologist/oncologist and as an industry leader in large pharmaceutical, health technology, and emerging biotechnology companies.

Mike will be instrumental in helping to drive innovative medical and scientific strategies to support OJEMDA’s growth while also continuing to build our pipeline of first- or best-in-class medicines for patients of all ages with life-threatening diseases.

Read more: https://t.co/zGtcmBKxpM

[Day One Biopharmaceuticals @DayOneBio]

Day One will be participating in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference in Miami on Tuesday, June 10th. Learn more about our pipeline and commitment to developing and commercializing targeted therapies for people of all ages living with life-threatening diseases.

View the webcast here: https://t.co/NHTSrQWTPp

[Day One Biopharmaceuticals @DayOneBio]

We're gearing up for this year's @ASCO Annual Meeting and we're excited to see everyone in Chicago! #ASCO25 abstracts include data from the FIREFLY-1 study in pediatric low-grade glioma (pLGG):

📌Abstract 10029 on growth recovery in patients with BRAF-altered pLGG after discontinuing tovorafenib

📌Abstract 10037 on a post hoc analysis of rashes reported in  relapsed/refractory pLGG patients treated with tovorafenib

If you're attending, stop by booth 34149 to meet the Day One team and learn more about how we're bringing novel targeted therapies to children and adults with cancer.

[Day One Biopharmaceuticals @DayOneBio]

The Day One team is excited to be at the 2025 @ASPHO_hq Conference in Louisville this week! Stop by our booth 113 to hear how we're redefining what's possible for people of all ages living with cancer. #ASPHO2025

Learn more about our mission here: https://t.co/9M1o2DWBJ9

[Day One Biopharmaceuticals @DayOneBio]

Day One reports first quarter 2025 financial results. Read more: https://t.co/SALLRy3OkC